Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG-501 for Cognitive Impairment in SLE
NCT07281105Phase 2Completed
- Sponsor
- Evergreen Therapeutics, Inc.
- Start
- Aug 2018
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of EG-501 in cognitive impairment, neuropsychiatric systemic lupus erythematosus (NPSLE), sponsored by Evergreen Therapeutics, Inc.. Started Aug 2018; status: completed.
02
Drugs
EG-501
03
Conditions
cognitive impairmentneuropsychiatric systemic lupus erythematosus (NPSLE)
Beyond the preview
Go deeper on NCT07281105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281105.